

# Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V:

Brexucabtagene Autoleucel (Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukaemia);  
Requirement of Routine Practice Data Collection and Evaluations

of 20 July 2023

The Federal Joint Committee (G-BA) decided the following at its session on 20 July 2023:

- I. The consultation procedure on the requirement of routine data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient brexucabtagene autoleucel for the treatment of

"Adults 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)."

is suspended.

- II. The resolution will enter into force on the day of its publication on the internet on the G-BA website on 20 July 2023.

The justification to this resolution will be published on the website of the G-BA at [www.g-ba.de](http://www.g-ba.de).

Berlin, 20 July 2023

Federal Joint Committee (G-BA)  
in accordance with Section 91 SGB V  
The Chair

Prof. Hecken